Journal: European Endocrinology

Article Title: Selecting the Appropriate Continuous Glucose Monitoring System – a Practical Approach

doi: 10.17925/EE.2018.14.1.24

Figure Lengend Snippet: Summary of characteristics and features of the Abbott Libre, Dexcom G5 and Medtronic Enlite systems as indicated for use outside the US

Article Snippet: This expanded interoperability allows users to analyse their Dexcom G5 glucose data in conjunction with a variety of devices and health support apps and programmes.

Techniques:

Journal: European Endocrinology

Article Title: Selecting the Appropriate Continuous Glucose Monitoring System – a Practical Approach

doi: 10.17925/EE.2018.14.1.24

Figure Lengend Snippet: Summary of characteristics and features of the Abbott Libre, Dexcom G5 and Medtronic Enlite systems as indicated for use outside the US

Article Snippet: This expanded interoperability allows users to analyse their Dexcom G5 glucose data in conjunction with a variety of devices and health support apps and programmes.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a

Article Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a Table A15: Intervention Brands (Approved in Canada) Diabetes Treatment Supplies Insulin Treatment CGM Insulin Pump Total Cost SAP Dexcom G4 Platinum + Animas Vibe $1,066 $734 $5,720 $4,290 $11,811 SAP Dexcom G5 Mobile + Animas Vibe or MiniMed VEO $533 $734 $5,976 $4,290 $11,534 SAP with LGS MiniMed Veo with LGS $1,066 $734 $3,120 $4,290 $9,211 CGM + MDI Dexcom G4 Platinum $2,329 $1,348 $6,420 — $10,097 CGM + MDI Dexcom G5 Mobile $1,263 $1,348 $5,976 — $8,587 SMBG + insulin pump Animas Vibe and MiniMed Veo $1,599 $734 — $4,484 $6,817 SMBG + MDI $2,329 $1,348 — — $3,677 Open in a separate window Abbreviations: CGM, continuous glucose monitoring; LGS, low-glucose suspend; MDI, multiple daily injections; SAP, sensor-augmented pump; SMBG, self-monitoring of blood glucose. a All costs are presented in 2017 Canadian dollars.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a

Article Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a Table A15: Intervention Brands (Approved in Canada) Diabetes Treatment Supplies Insulin Treatment CGM Insulin Pump Total Cost SAP Dexcom G4 Platinum + Animas Vibe $1,066 $734 $5,720 $4,290 $11,811 SAP Dexcom G5 Mobile + Animas Vibe or MiniMed VEO $533 $734 $5,976 $4,290 $11,534 SAP with LGS MiniMed Veo with LGS $1,066 $734 $3,120 $4,290 $9,211 CGM + MDI Dexcom G4 Platinum $2,329 $1,348 $6,420 — $10,097 CGM + MDI Dexcom G5 Mobile $1,263 $1,348 $5,976 — $8,587 SMBG + insulin pump Animas Vibe and MiniMed Veo $1,599 $734 — $4,484 $6,817 SMBG + MDI $2,329 $1,348 — — $3,677 Open in a separate window Abbreviations: CGM, continuous glucose monitoring; LGS, low-glucose suspend; MDI, multiple daily injections; SAP, sensor-augmented pump; SMBG, self-monitoring of blood glucose. a All costs are presented in 2017 Canadian dollars.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Costs of Different Diabetes Treatment Technologies a

Article Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a Table A15: Intervention Brands (Approved in Canada) Diabetes Treatment Supplies Insulin Treatment CGM Insulin Pump Total Cost SAP Dexcom G4 Platinum + Animas Vibe $1,066 $734 $5,720 $4,290 $11,811 SAP Dexcom G5 Mobile + Animas Vibe or MiniMed VEO $533 $734 $5,976 $4,290 $11,534 SAP with LGS MiniMed Veo with LGS $1,066 $734 $3,120 $4,290 $9,211 CGM + MDI Dexcom G4 Platinum $2,329 $1,348 $6,420 — $10,097 CGM + MDI Dexcom G5 Mobile $1,263 $1,348 $5,976 — $8,587 SMBG + insulin pump Animas Vibe and MiniMed Veo $1,599 $734 — $4,484 $6,817 SMBG + MDI $2,329 $1,348 — — $3,677 Open in a separate window Abbreviations: CGM, continuous glucose monitoring; LGS, low-glucose suspend; MDI, multiple daily injections; SAP, sensor-augmented pump; SMBG, self-monitoring of blood glucose. a All costs are presented in 2017 Canadian dollars.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Estimated Annual Per-Patient Costs of Continuous Glucose Monitoring When Insulin Pump, Insulin, and Supplies Are Publicly Funded

Article Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a Table A15: Intervention Brands (Approved in Canada) Diabetes Treatment Supplies Insulin Treatment CGM Insulin Pump Total Cost SAP Dexcom G4 Platinum + Animas Vibe $1,066 $734 $5,720 $4,290 $11,811 SAP Dexcom G5 Mobile + Animas Vibe or MiniMed VEO $533 $734 $5,976 $4,290 $11,534 SAP with LGS MiniMed Veo with LGS $1,066 $734 $3,120 $4,290 $9,211 CGM + MDI Dexcom G4 Platinum $2,329 $1,348 $6,420 — $10,097 CGM + MDI Dexcom G5 Mobile $1,263 $1,348 $5,976 — $8,587 SMBG + insulin pump Animas Vibe and MiniMed Veo $1,599 $734 — $4,484 $6,817 SMBG + MDI $2,329 $1,348 — — $3,677 Open in a separate window Abbreviations: CGM, continuous glucose monitoring; LGS, low-glucose suspend; MDI, multiple daily injections; SAP, sensor-augmented pump; SMBG, self-monitoring of blood glucose. a All costs are presented in 2017 Canadian dollars.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Estimated Annual Per-Patient Costs (All Direct Medical Costs) of Continuous Glucose Monitoring in Ontario

Article Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a Table A15: Intervention Brands (Approved in Canada) Diabetes Treatment Supplies Insulin Treatment CGM Insulin Pump Total Cost SAP Dexcom G4 Platinum + Animas Vibe $1,066 $734 $5,720 $4,290 $11,811 SAP Dexcom G5 Mobile + Animas Vibe or MiniMed VEO $533 $734 $5,976 $4,290 $11,534 SAP with LGS MiniMed Veo with LGS $1,066 $734 $3,120 $4,290 $9,211 CGM + MDI Dexcom G4 Platinum $2,329 $1,348 $6,420 — $10,097 CGM + MDI Dexcom G5 Mobile $1,263 $1,348 $5,976 — $8,587 SMBG + insulin pump Animas Vibe and MiniMed Veo $1,599 $734 — $4,484 $6,817 SMBG + MDI $2,329 $1,348 — — $3,677 Open in a separate window Abbreviations: CGM, continuous glucose monitoring; LGS, low-glucose suspend; MDI, multiple daily injections; SAP, sensor-augmented pump; SMBG, self-monitoring of blood glucose. a All costs are presented in 2017 Canadian dollars.

Techniques:

Journal: Ontario Health Technology Assessment Series

Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment

doi:

Figure Lengend Snippet: Estimated Annual Per-Patient Costs of Continuous Glucose Monitoring when Insulin Pump, Insulin, and 75% of Sensor Costs Are Publicly Funded

Article Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a Table A15: Intervention Brands (Approved in Canada) Diabetes Treatment Supplies Insulin Treatment CGM Insulin Pump Total Cost SAP Dexcom G4 Platinum + Animas Vibe $1,066 $734 $5,720 $4,290 $11,811 SAP Dexcom G5 Mobile + Animas Vibe or MiniMed VEO $533 $734 $5,976 $4,290 $11,534 SAP with LGS MiniMed Veo with LGS $1,066 $734 $3,120 $4,290 $9,211 CGM + MDI Dexcom G4 Platinum $2,329 $1,348 $6,420 — $10,097 CGM + MDI Dexcom G5 Mobile $1,263 $1,348 $5,976 — $8,587 SMBG + insulin pump Animas Vibe and MiniMed Veo $1,599 $734 — $4,484 $6,817 SMBG + MDI $2,329 $1,348 — — $3,677 Open in a separate window Abbreviations: CGM, continuous glucose monitoring; LGS, low-glucose suspend; MDI, multiple daily injections; SAP, sensor-augmented pump; SMBG, self-monitoring of blood glucose. a All costs are presented in 2017 Canadian dollars.

Techniques:

Journal: Journal of the Endocrine Society

Article Title: A Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System to Manage Children and Adolescents With Diabetes

doi: 10.1210/js.2017-00389

Figure Lengend Snippet: Education Checklist When Using rtCGM

Article Snippet: Dexcom G5 Mobile only requires Bluetooth capability and can use Wi-Fi to send data, and Dexcom Follow can receive data via Wi-Fi, obviating the need for costly mobile data plans for young patients sharing as well as adult caregivers who want to “follow.” Use of data sharing varies, especially across the pediatric age span.

Techniques:

Journal: Journal of the Endocrine Society

Article Title: A Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System to Manage Children and Adolescents With Diabetes

doi: 10.1210/js.2017-00389

Figure Lengend Snippet: Dexcom G5 trend arrows. Dexcom G5 presents trend arrow data as icons on the Dexcom G5 Receiver and on the Dexcom G5 Mobile and Follow mobile apps (App) on compatible smart devices. According to the manufacturer, trend arrows indicate rates of glucose change (mg/dL per minute) and can be described as the anticipated glucose change in 30 minutes. Notably, the FLAT arrow (➡) indicates steady but does not indicate zero change. Note that trend arrows are determined by recent rtCGM measurements (generally the most recent 10 minutes of glucose values). In general, anticipated glucose may be less accurate when trying to predict changes over extended periods of time (e.g., beyond 20 to 30 minutes) due to the many factors that may influence glucose levels. Conversion: mg/dL × 0.0555 = mmol/L.

Article Snippet: Dexcom G5 Mobile only requires Bluetooth capability and can use Wi-Fi to send data, and Dexcom Follow can receive data via Wi-Fi, obviating the need for costly mobile data plans for young patients sharing as well as adult caregivers who want to “follow.” Use of data sharing varies, especially across the pediatric age span.

Techniques:

Journal: Journal of the Endocrine Society

Article Title: A Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System to Manage Children and Adolescents With Diabetes

doi: 10.1210/js.2017-00389

Figure Lengend Snippet: New approach to adjust insulin doses using trend arrows in pediatric patients with diabetes. This figure outlines our approach to adjusting insulin doses using trend arrow data from the Dexcom G5 system in pediatric patients with diabetes receiving rapid acting insulin analogs. The approach is based on anticipated glucose change and typical insulin sensitivity ranges in pediatric patients that correspond to developmental stages. It should be noted that insulin sensitivity is generally greater in younger, prepubertal patients and decreases over time as youth age with decreasing insulin sensitivity associated with pubertal growth and development. The approach to adjusting insulin doses using trend arrows is suggested for premeal boluses and for corrections 3 or more hours following a meal. In general, the authors recommend avoiding adjustments using trend arrows immediately following meals due to the variability that ingested carbohydrates can have on trend arrows. Generally, one should begin with conservative adjustments to understand how the dose changes impact the individual. It is essential to understand that adjusting insulin doses using trend arrows does not replace but adds to standard calculations using ICR and CF. The approach assumes the patient has insulin requiring diabetes, is using rapid-acting insulin for meals and correction, and is using ICR and CF factors that have been accurately determined by the patient’s health care team ( e.g., determining CF using the 1500 to 1800 rule) . Conversion: mg/dL × 0.0555 = mmol/L. CF, correction factor in mg/dL, indicates glucose lowering per unit of rapid-acting insulin; U, units of rapid-acting insulin.

Article Snippet: Dexcom G5 Mobile only requires Bluetooth capability and can use Wi-Fi to send data, and Dexcom Follow can receive data via Wi-Fi, obviating the need for costly mobile data plans for young patients sharing as well as adult caregivers who want to “follow.” Use of data sharing varies, especially across the pediatric age span.

Techniques:

Journal: Journal of the Endocrine Society

Article Title: A Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System to Manage Children and Adolescents With Diabetes

doi: 10.1210/js.2017-00389

Figure Lengend Snippet: Case Examples to Put Our Approach Into Practice for Children and Adolescents

Article Snippet: Dexcom G5 Mobile only requires Bluetooth capability and can use Wi-Fi to send data, and Dexcom Follow can receive data via Wi-Fi, obviating the need for costly mobile data plans for young patients sharing as well as adult caregivers who want to “follow.” Use of data sharing varies, especially across the pediatric age span.

Techniques:

Journal: Journal of Endocrinological Investigation

Article Title: Implantable and transcutaneous continuous glucose monitoring system: a randomized cross over trial comparing accuracy, efficacy and acceptance

doi: 10.1007/s40618-021-01624-2

Figure Lengend Snippet: Participant characteristics

Article Snippet: In a randomized crossover trial we compared 12 weeks with Eversense implantable sensor (EVS) and 12 weeks with Dexcom G5 transcutaneous sensor (DG5) in terms of accuracy, evaluated as Mean Absolute Relative Difference (MARD) vs capillary glucose (SMBG), time of CGM use, adverse events, efficacy (as HbA1c, time in range, time above and below range) and psychological outcomes evaluated with Diabetes Treatment Satisfaction Questionnaire (DTSQ), Glucose Monitoring Satisfaction Survey (GMSS), Hypoglycemia Fear Survey (HFS2), Diabetes Distress Scale (DDS).

Techniques:

Journal: Journal of Endocrinological Investigation

Article Title: Implantable and transcutaneous continuous glucose monitoring system: a randomized cross over trial comparing accuracy, efficacy and acceptance

doi: 10.1007/s40618-021-01624-2

Figure Lengend Snippet: Total data collected during DG5 and EVS use and percentage of use when sensor was active

Article Snippet: In a randomized crossover trial we compared 12 weeks with Eversense implantable sensor (EVS) and 12 weeks with Dexcom G5 transcutaneous sensor (DG5) in terms of accuracy, evaluated as Mean Absolute Relative Difference (MARD) vs capillary glucose (SMBG), time of CGM use, adverse events, efficacy (as HbA1c, time in range, time above and below range) and psychological outcomes evaluated with Diabetes Treatment Satisfaction Questionnaire (DTSQ), Glucose Monitoring Satisfaction Survey (GMSS), Hypoglycemia Fear Survey (HFS2), Diabetes Distress Scale (DDS).

Techniques:

Journal: Journal of Endocrinological Investigation

Article Title: Implantable and transcutaneous continuous glucose monitoring system: a randomized cross over trial comparing accuracy, efficacy and acceptance

doi: 10.1007/s40618-021-01624-2

Figure Lengend Snippet: Glycemic control during EVS and DG5 sensor use

Article Snippet: In a randomized crossover trial we compared 12 weeks with Eversense implantable sensor (EVS) and 12 weeks with Dexcom G5 transcutaneous sensor (DG5) in terms of accuracy, evaluated as Mean Absolute Relative Difference (MARD) vs capillary glucose (SMBG), time of CGM use, adverse events, efficacy (as HbA1c, time in range, time above and below range) and psychological outcomes evaluated with Diabetes Treatment Satisfaction Questionnaire (DTSQ), Glucose Monitoring Satisfaction Survey (GMSS), Hypoglycemia Fear Survey (HFS2), Diabetes Distress Scale (DDS).

Techniques: Standard Deviation